Literature DB >> 26535021

Edoxaban (Savaysa): A Factor Xa Inhibitor.

Lewey Chan, Michele Pisano.   

Abstract

Entities:  

Year:  2015        PMID： 26535021      PMCID： PMC4606855     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  7 in total

1.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Atrial fibrillation and stroke: epidemiology.

Authors:  James A Reiffel
Journal:  Am J Med       Date:  2014-04       Impact factor: 4.965

Review 4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

5.  Increasing prevalence of atrial fibrillation and flutter in the United States.

Authors:  Gerald V Naccarelli; Helen Varker; Jay Lin; Kathy L Schulman
Journal:  Am J Cardiol       Date:  2009-12-01       Impact factor: 2.778

6.  Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.

Authors:  Donald M Lloyd-Jones; Thomas J Wang; Eric P Leip; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Ralph B D'Agostino; Joseph M Massaro; Alexa Beiser; Philip A Wolf; Emelia J Benjamin
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

7.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245
  7 in total
  5 in total

1.  Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.

Authors:  Joshua D Brown; Anand R Shewale; Jeffery C Talbert
Journal:  J Manag Care Spec Pharm       Date:  2016-11

2.  Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.

Authors:  Shannon L Reynolds; Sameer R Ghate; Richard Sheer; Pranav K Gandhi; Chad Moretz; Cheng Wang; Stephen Sander; Mary E Costantino; Srinivas Annavarapu; George Andrews
Journal:  Health Qual Life Outcomes       Date:  2017-06-21       Impact factor: 3.186

3.  Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?

Authors:  Phuong N Pham; Joshua D Brown
Journal:  BMC Cardiovasc Disord       Date:  2019-03-19       Impact factor: 2.298

4.  Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria.

Authors:  Takuro Takama; Mitsunori Fukue; Koji Kanaya; Masato Taniuchi
Journal:  SAGE Open Med Case Rep       Date:  2019-09-23

5.  Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.

Authors:  Joshua D Brown; Anand R Shewale; Jeffery C Talbert
Journal:  J Manag Care Spec Pharm       Date:  2017-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.